Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy
- Publication type:
- Journal article
- Metadata:
-
- Abstract
- <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background:</jats:title> <jats:p>Shexiang Baoxin Pill (SBP) is one of the most commonly used traditional Chinese patent medicines for cardiovascular diseases. This systematic review was designed to provide rigorous therapeutic efficacy and safety evidence on the use of SBP combined with trimetazidine in elderly patients with heart failure (HF) secondary to ischaemic cardiomyopathy (ICM).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Relevant randomized controlled trials (RCTs) investigating the clinical efficacy of SBP combined with trimetazidine in treating ICM-associated HF were widely searched in electronic databases, including PubMed, Cochrane library, EMBASE, CBM, CNKI, VMIS, and Wanfang up to January 1, 2018. The methodological quality of each trial was assessed according to the Cochrane Reviewers’ Handbook 5.0. Meta-analysis was performed by using Review Manager 5.3.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Eighteen RCTs (N = 1532) that met the criteria were included in the review for the assessment of methodological quality. Meta-analysis showed that, when compared with conventional therapy, SBP combined with trimetazidine significantly improved the clinical efficacy and indices of cardiac function (including increasing left ventricular ejection fraction [LVEF] and 6-minute walk distance [6-MWD], decreasing left ventricular end-diastolic diameter [LVEDD] and left ventricular end-systolic diameter [LVESD]) without serious adverse reactions.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>This work provides evidence of the benefit of SBP combined with trimetazidine for the treatment of HF secondary to ICM. More high quality and well-designed RCTs are needed to confirm these findings.</jats:p> </jats:sec>
- Autoren
- Jianxia Wen
- Xiao Ma
- Lu Zhang
- Xiaohua Lu
- Yuxue Yang
- Jian Wang
- Yanling Zhao
- DOI
- 10.1097/md.0000000000013580
- eISSN
- 1536-5964
- ISSN
- 0025-7974
- Ausgabe der Veröffentlichung
- 51
- Zeitschrift
- Medicine
- Sprache
- en
- Paginierung
- e13580 - e13580
- Datum der Veröffentlichung
- 2018
- Status
- Published
- Herausgeber
- Ovid Technologies (Wolters Kluwer Health)
- Herausgeber URL
- http://dx.doi.org/10.1097/md.0000000000013580
- Datum der Datenerfassung
- 2023
- Titel
- Therapeutic efficacy and safety of Shexiang Baoxin Pill combined with trimetazidine in elderly patients with heart failure secondary to ischaemic cardiomyopathy
- Ausgabe der Zeitschrift
- 97
Data source: Crossref
- Other metadata sources:
-
- Beziehungen:
- Property of